Halozyme Therapeutics, Inc. HALO

$106.94 -3.13% at last close

Recent SEC Filings

FormDescriptionFiledDocument
8-K 8-K 2026-09-30 View →
8-K 8-K 2026-09-22 View →
8-K 8-K 2026-09-18 View →
4 FORM 4 2026-09-17 View →
8-K 8-K 2026-09-16 View →
4 FORM 4 2026-09-11 View →
4 FORM 4 2026-09-02 View →
4 FORM 4 2026-08-19 View →
8-K 8-K 2026-08-18 View →
4 FORM 4 2026-08-11 View →
10-Q 10-Q 2026-08-06 View →
8-K 8-K 2026-08-06 View →
4 FORM 4 2026-07-09 View →
4 FORM 4 2026-07-02 View →
4 FORM 4 2026-07-02 View →
4 FORM 4 2026-07-02 View →
8-K 8-K 2026-07-02 View →
4 FORM 4 2026-06-30 View →
4 FORM 4 2026-06-15 View →
4 FORM 4 2026-06-03 View →
4 FORM 4 2026-06-02 View →
4 FORM 4 2026-05-13 View →
10-Q 10-Q 2026-05-11 View →
8-K 8-K 2026-05-11 View →
4 FORM 4 2026-05-07 View →
4 FORM 4 2026-05-07 View →
4 FORM 4 2026-05-07 View →
4 FORM 4 2026-05-07 View →
4 FORM 4 2026-05-07 View →
4 FORM 4 2026-05-07 View →
8-K 8-K 2026-05-07 View →
4 FORM 4 2026-05-05 View →
8-K 8-K 2026-04-30 View →
8-K 8-K 2026-04-24 View →
4 FORM 4 2026-04-07 View →
4 FORM 4 2026-04-02 View →
4 FORM 4 2026-04-02 View →
DEF 14A DEF 14A 2026-03-23 View →
8-K 8-K 2026-03-12 View →
4 FORM 4 2026-03-10 View →

Filings are sourced directly from the SEC's EDGAR system. Annual reports (10-K) and quarterly reports (10-Q) carry the full financial statements; 8-K filings disclose material events between reports; Form 4 filings record insider purchases and sales.

Key Stats

Last Close
$106.94
Market Cap
$12.53 billion
52-Week Range
$61.23 – $116.84
Average Volume
2.18 million shs

Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.